AI-generated summary
This review describes earlier studies of photobiomodulation in neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease and epilepsy. The authors report positive effects in animal research but note that few clinical studies have shown positive outcomes. They conclude that the exact mechanism and an effective clinical protocol still need to be determined.
- Who or what was studied
- Patients with neurodegenerative disorders (Alzheimer's disease, Parkinson's disease, epilepsy); the review draws mainly on animal research
- Limits stated in the abstract
- The abstract notes that many findings come from animal studies, few clinical studies have shown positive results, and the mechanism and effective clinical protocol remain undetermined.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.